Literature DB >> 9733845

Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Z C Neal1, G A Splitter.   

Abstract

Although the ability of serum-neutralizing antibodies to protect against picornavirus infection is well established, the contribution of cell-mediated immunity to protection is uncertain. Using major histocompatibility complex class II-deficient (RHAbeta-/-) mice, which are unable to mediate CD4(+) T-lymphocyte-dependent humoral responses, we demonstrated antibody-independent protection against lethal encephalomyocarditis virus (EMCV) infection in the natural host. The majority of RHAbeta-/- mice inoculated with 10(4) PFU of attenuated Mengo virus (vMC24) resolved infection and were resistant to lethal challenge with the highly virulent, serotypically identical cardiovirus, EMCV. Protection in these mice was in the absence of detectable serum-neutralizing antibodies. Depletion of CD8(+) T lymphocytes prior to lethal EMCV challenge ablated protection in vMC24-immunized RHAbeta-/- mice. The CD8(+) T-lymphocyte-dependent protection observed in vivo may, in part, be the result of cytotoxic T-lymphocyte (CTL) activity, as CD8(+) T splenocytes exhibited in vitro cytolysis of EMCV-infected targets. The existence of virus-specific CD8(+) T-lymphocyte memory in these mice was demonstrated by increased expression of cell surface activation markers CD25, CD69, CD71, and CTLA-4 following antigen-specific reactivation in vitro. Although recall response in vMC24-immunized RHAbeta-/- mice was intact and effectual shortly after immunization, protection abated over time, as only 3 of 10 vMC24-immunized RHAbeta-/- mice survived when rechallenged 90 days later. The present study demonstrating CD8(+) T-lymphocyte-dependent protection in the absence of serum-neutralizing antibodies, coupled with our previous results indicating that vMC24-specific CD4(+) T lymphocytes confer protection against lethal EMCV in the absence of prophylactic antibodies, suggests the existence of nonhumoral protective mechanisms against picornavirus infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733845      PMCID: PMC110142     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  An early, abundant cytotoxic T-lymphocyte response against Theiler's virus is critical for preventing viral persistence.

Authors:  S Dethlefs; M Brahic; E L Larsson-Sciard
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Cytotoxic T lymphocytes and natural killer cell activity in the course of mengo virus infection of mice.

Authors:  D Hassin; R Fixler; H Bank; A S Klein; Y Hasin
Journal:  Immunology       Date:  1985-12       Impact factor: 7.397

3.  Cellular pathways for rejection of class-I-MHC--disparate skin and tumor allografts.

Authors:  D M Smith; F P Stuart; G A Wemhoff; J Quintáns; F W Fitch
Journal:  Transplantation       Date:  1988-01       Impact factor: 4.939

Review 4.  Strategy for construction of live picornavirus vaccines.

Authors:  A Nomoto; N Iizuka; M Kohara; M Arita
Journal:  Vaccine       Date:  1988-04       Impact factor: 3.641

5.  Dynamic model of the pathogenesis of Mengo virus infection in mice.

Authors:  R Guthke; A Veckenstedt; J Güttner; R Stracke; F Bergter
Journal:  Acta Virol       Date:  1987-08       Impact factor: 1.162

6.  Pathogenicity of mengo virus to mice. I. Virological studies.

Authors:  A Veckenstedt
Journal:  Acta Virol       Date:  1974-11       Impact factor: 1.162

7.  Cloning and synthesis of infectious cardiovirus RNAs containing short, discrete poly(C) tracts.

Authors:  G M Duke; A C Palmenberg
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

8.  Survival of athymic (nu/nu) mice after Theiler's murine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody.

Authors:  R S Fujinami; A Rosenthal; P W Lampert; A Zurbriggen; M Yamada
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

9.  Treatment of encephalomyocarditis virus-induced central nervous system demyelination with monoclonal anti-T-cell antibodies.

Authors:  S Sriram; D J Topham; S K Huang; M Rodriguez
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

10.  The effect of L3T4 T cell depletion on the pathogenesis of Theiler's murine encephalomyelitis virus infection in CBA mice.

Authors:  C J Welsh; P Tonks; A A Nash; W F Blakemore
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

View more
  6 in total

1.  CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.

Authors:  Petr O Ilyinskii; Ruojie Wang; Steven P Balk; Mark A Exley
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Innate immune response to encephalomyocarditis virus infection mediated by CD1d.

Authors:  Mark A Exley; Nancy J Bigley; Olivia Cheng; Angela Shaulov; Syed Muhammad Ali Tahir; Quincy L Carter; Jorge Garcia; Carren Wang; Kurt Patten; Harold F Stills; Frederick W Alt; Scott B Snapper; Steven P Balk
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

Review 3.  Engineering universal cells that evade immune detection.

Authors:  Robert Lanza; David W Russell; Andras Nagy
Journal:  Nat Rev Immunol       Date:  2019-08-15       Impact factor: 53.106

4.  Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.

Authors:  Nikolaus Rieber; Anna Graf; Dominik Hartl; Simon Urschel; Bernd H Belohradsky; Johannes Liese
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

5.  MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.

Authors:  Autumn J Ruiz; Elizabeth M Hadac; Rebecca A Nace; Stephen J Russell
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 6.  The long-lasting enigma of polycytidine (polyC) tract.

Authors:  Velia Penza; Stephen J Russell; Autumn J Schulze
Journal:  PLoS Pathog       Date:  2021-08-04       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.